Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Myo-Inositol wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
7 of 12 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Myo-Inositol and Tirzepatide have evidence — compare verdict strength side-by-side.
2-4g daily for PCOS; up to 12-18g for anxiety
Divided doses with meals, Morning and evening
Myo-inositol powder
Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)
any
Once-weekly subcutaneous injection (Mounjaro / Zepbound)
3-6 months
4-6 weeks
2-3 months
Initial use or high doses
Weeks to months
Months (dose-escalated over ~20 weeks)
Weeks to months
Mostly during titration
Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes
The Cochrane database of systematic reviews (2023) · Meta analysis · n=1319
For the primary neonatal outcomes, only one study measured the risk of a large-for-gestational-age infant and found myo-inositol was associated with both appreciable benefit and harm (RR 1.40, 95% CI 0.65 to 3.02; 1 study, 234 infants; low-certainty evidence).
Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Nutrients (2022) · Meta analysis · n=1321
Pooled results were expressed as relative risk (RR) or mean difference (MD) with a 95% confidence interval (95% CI).
Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials
European review for medical and pharmacological sciences (2022) · Meta analysis · n=612
Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs).
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=1879
Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med (2022) · Rct · n=2539
72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
N Engl J Med (2025) · Rct · n=751
Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide
Based on multiple meta-analyses showing improved menstrual regularity and ovulation in PCOS. Evidence quality varies across studies with some showing minimal differences vs placebo. 4g daily most commonly studied dose.
AI-estimated from published studies. Interpret as directional guidance.
Myo-Inositol has a higher evidence score (7/10 vs 7.8/10) and wins in 2 of 3 categories.
No known interactions between Myo-Inositol and Tirzepatide have been documented in our database. However, always consult a healthcare provider before combining supplements.